Basilea News http://www.basilea.com/ Basilea News en Tue, 01 Sep 2015 12:04:27 +0200 Tue, 01 Sep 2015 12:04:27 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor]]> http://www.basilea.com/News-and-Media/Basileas-Chief-Technology-Officer-Dr-Ingrid-Heinze-Krauss-to-retire-and-Dr-Guenter-Ditzinger-named-as-successor/cf780367-0cc2-9dc4-19ea-dcb4f2f83820 Fri, 28 Aug 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basileas-Chief-Technology-Officer-Dr-Ingrid-Heinze-Krauss-to-retire-and-Dr-Guenter-Ditzinger-named-as-successor/cf780367-0cc2-9dc4-19ea-dcb4f2f83820 <![CDATA[Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®]]> http://www.basilea.com/News-and-Media/Basilea-reports-2015-half-year-results-Major-milestones-achieved-for-CRESEMBA-and-Zevtera/8cd5fd46-684f-247f-ef91-f9c42113a5a7
  • Antifungal CRESEMBA® (isavuconazole) received U.S. approval and is recommended for approval in the European Union
  • Antibiotic Zevtera®/Mabelio® (ceftobiprole medocaril) launched in four European countries
  • Ceftobiprole designated as a Qualified Infectious Disease Product for the treatment of lung and skin infections by U.S. FDA
  • Additional oncology program (panRAF kinase inhibitor BAL3833) entered phase 1 of clinical development
  • Cash and short-term investments of CHF 218.4 million
  • ]]>
    Fri, 14 Aug 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-2015-half-year-results-Major-milestones-achieved-for-CRESEMBA-and-Zevtera/8cd5fd46-684f-247f-ef91-f9c42113a5a7
    <![CDATA[Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-ceftobiprole-received-QIDP-designation-from-U-S-FDA-for-the-treatment-of-lung-and-skin-infections/fb31ecf6-1c1c-da91-bcfc-d7464604a1c8 Wed, 12 Aug 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-that-ceftobiprole-received-QIDP-designation-from-U-S-FDA-for-the-treatment-of-lung-and-skin-infections/fb31ecf6-1c1c-da91-bcfc-d7464604a1c8 <![CDATA[Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections]]> http://www.basilea.com/News-and-Media/Basilea-reports-topline-results-of-isavuconazole-phase-3-study-in-candidemia-and-other-invasive-Candida-infections/ad57a059-7468-9d46-e1d7-c90ee595a796 Thu, 30 Jul 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-topline-results-of-isavuconazole-phase-3-study-in-candidemia-and-other-invasive-Candida-infections/ad57a059-7468-9d46-e1d7-c90ee595a796 <![CDATA[Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union]]> http://www.basilea.com/News-and-Media/Basilea-announces-that-CHMP-recommends-approval-of-isavuconazole-CRESEMBA-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-European-Union/c01a300d-fe10-06a1-6b5c-de29e60fe0ec Fri, 24 Jul 2015 13:44:38 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-that-CHMP-recommends-approval-of-isavuconazole-CRESEMBA-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-European-Union/c01a300d-fe10-06a1-6b5c-de29e60fe0ec <![CDATA[Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553]]> http://www.basilea.com/News-and-Media/Basilea-initiates-phase-1-2a-oncology-study-with-oral-formulation-of-tumor-checkpoint-controller-BAL101553/e8b0d2b5-df5a-5eaf-ed49-a24b1e981d6a Thu, 25 Jun 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-initiates-phase-1-2a-oncology-study-with-oral-formulation-of-tumor-checkpoint-controller-BAL101553/e8b0d2b5-df5a-5eaf-ed49-a24b1e981d6a <![CDATA[Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor]]> http://www.basilea.com/News-and-Media/Basilea-reports-start-of-first-in-human-phase-1-oncology-study-with-oral-panRAF-kinase-inhibitor/407433b0-37e7-b20b-53c1-c405cce13192 Mon, 04 May 2015 19:38:45 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-start-of-first-in-human-phase-1-oncology-study-with-oral-panRAF-kinase-inhibitor/407433b0-37e7-b20b-53c1-c405cce13192 <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7fe480dc-bd41-b275-5dea-141918a121b9 Wed, 29 Apr 2015 17:57:42 +0200 http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7fe480dc-bd41-b275-5dea-141918a121b9 <![CDATA[Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID]]> http://www.basilea.com/News-and-Media/Basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-ECCMID/4e2c5bf7-ad8b-7c66-c933-cc88ab9436b0 Fri, 24 Apr 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-ECCMID/4e2c5bf7-ad8b-7c66-c933-cc88ab9436b0 <![CDATA[Basilea in-licenses targeted cancer therapy]]> http://www.basilea.com/News-and-Media/Basilea-in-licenses-targeted-cancer-therapy/7593c3a4-0959-18e7-2e1d-2df5872064a1 Wed, 01 Apr 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-in-licenses-targeted-cancer-therapy/7593c3a4-0959-18e7-2e1d-2df5872064a1